Association of PYGO2 and EGFR in esophageal squamous cell carcinoma

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Moghbeli, Meysam ^a   Abbaszadegan, Mohammad Reza ^a,b   Farshchian, Moein ^c   Montazer, Mehdi ^d   Raeisossadati, Reza ^e   Abdollahi, Abbas ^f   Forghanifard, Mohammad Mahdi ^e  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c FERDOWSI UNIVERSITY OF MASHHAD   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ISLAMIC AZAD UNIVERSITY   (Iran)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

EGFR; Esophageal squamous cell carcinoma; Expressional analysis; PYGO2; Real time PCR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN; PYGO2 PROTEIN; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; PYGO2 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SIZE; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; UPREGULATION; BIOSYNTHESIS; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84874376545     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0516-9     Document Type: Article

References (67)

1. Gholamin M, Moaven O, Memar B, Farshchian M, Naseh H, Malekzadeh R, et al. Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg. 2009;33(7):1439-45.
2. Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22(1):1-8.
3. Headrick JR, Nichols FC III, Miller DL, Allen MS, Trastek VF, Deschamps C et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg. 2002;73(6):1697-702; discussion 702-3.
4. Collard JM, Otte JB, Fiasse R, Laterre PF, De Kock M, Longueville J, et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg. 2001;234(1):25-32.
5. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662-9.
6. Morin PJ. beta-catenin signaling and cancer. BioEssays. 1999;21(12):1021-30.
7. Bienz M. Beta-Catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol. 2005;15(2):R64-7.
8. Pinto D, Clevers H. Wnt, stem cells and cancer in the intestine. Biol Cell. 2005;97(3):185-96.
9. Shapiro M, Akiri G, Chin C, Wisnivesky JP, Beasley MB, Weiser TS et al. Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg. 2013;257(3):548-54.
10. Daa T, Kashima K, Kaku N, Suzuki M, Yokoyama S. Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma. Mod Pathol. 2004;17(12):1475-82.
11. Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res. 2009;11(3):R32.
12. Parker DS, Jemison J, Cadigan KM. Pygopus, a nuclear PHD-finger protein required for Wingless signaling in Drosophila. Development. 2002;129(11):2565- 76.
13. Townsley FM, Cliffe A, Bienz M. Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol. 2004;6(7):626-33.
14. Townsley FM, Thompson B, Bienz M. Pygopus residues required for its binding to Legless are critical for transcription and development. J Biol Chem. 2004;279(7):5177-83.
15. Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, et al. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin Cancer Res. 2006;12(7 Pt 1):2216-23.
16. Andrews PG, Lake BB, Popadiuk C, Kao KR. Requirement of Pygopus 2 in breast cancer. Int J Oncol. 2007;30(2):357-63.
17. Fiedler M, Sanchez-Barrena MJ, Nekrasov M, Mieszczanek J, Rybin V, Muller J, et al. Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex. Mol Cell. 2008;30(4):507-18.
18. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC, et al. Active genes are tri-methylated at K4 of histone H3. Nature. 2002;419(6905):407-11.
19. Gu B, Sun P, Yuan Y, Moraes RC, Li A, Teng A, et al. Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation. J Cell Biol. 2009;185(5):811-26.
20. Horsley V. Epigenetics, Wnt signaling, and stem cells: the Pygo2 connection. J Cell Biol. 2009;185(5):761-3.
21. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003;284(1):99-110.
22. Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes Dev. 2000;14(9):1027-47.
23. Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol. 2005;32(1):52-60.
24. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001;158(4):1245-51.
25. Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liseman B, et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol. 1992;51(3):147-52.
26. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71(8):2454-60.
27. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer. 1993;68(1):162-5.
28. Yano H, Shiozaki H, Kobayashi K, Yano T, Tahara H, Tamura S, et al. Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma. Cancer. 1991;67(1):91-8.
29. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer. 1994;74(3):795-804.
30. Boone J, van Hillegersberg R, Offerhaus GJ, van Diest PJ, Borel Rinkes IH, Ten Kate FJ. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus. 2009;22(6):496-504.
31. Carneiro A, Isinger A, Karlsson A, Johansson J, Jonsson G, Bendahl PO, et al. Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. BMC Cancer. 2008;8:98.
32. Civenni G, Holbro T, Hynes NE. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep. 2003;4(2):166-71.
33. Wittekind C, Oberschmid B. TNM classification of malignant tumors 2010: general aspects and amendments in the general section. Pathologe. 2010;31(5):333-4, 6-8.
34. Rubie C, Kempf K, Hans J, Su T, Tilton B, Georg T, et al. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Mol Cell Probes. 2005;19(2):101-9.
35. Kelleher FC, Fennelly D, Rafferty M. Common critical pathways in embryogenesis and cancer. Acta Oncol. 2006;45(4):375-88.
36. Jessen S, Gu B, Dai X. Pygopus and the Wnt signaling pathway: a diverse set of connections. BioEssays. 2008;30(5):448-56.
37. Stadeli R, Basler K. Dissecting nuclear Wingless signalling: recruitment of the transcriptional co-activator Pygopus by a chain of adaptor proteins. Mech Dev. 2005;122(11):1171-82.
38. Krieghoff E, Behrens J, Mayr B. Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention. J Cell Sci. 2006;119(Pt 7):1453-63.
39. Chen J, Luo Q, Yuan Y, Huang X, Cai W, Li C et al. Pygo2 associates with MLL2 histone methyltransferase and GCN5 histone acetyltransferase complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion. Mol Cell Biol. 2010;30(24):5621-35.
40. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509-12.
41. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398(6726):422-6.
42. Thompson B, Townsley F, Rosin-Arbesfeld R, Musisi H, Bienz M. A new nuclear component of the Wnt signalling pathway. Nat Cell Biol. 2002;4(5):367-73.
43. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 2008;99(2):214-20.
44. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93(1):107-15.
45. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118(5):1173-80.
46. Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(2):111-9.
47. Yang YL, Xu KL, Zhou Y, Gao X, Chen LR. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas. Chin Med J (Engl). 2012;125(3):450-4.
48. Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. BMJ. 2009;338:b929.
49. Morita M, Kumashiro R, Kubo N, Nakashima Y, Yoshida R, Yoshinaga K et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol. 2010;15(2):126-34.
50. Hu T, Li C. Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer. 2010;9:236.
51. Heeg S, Hirt N, Queisser A, Schmieg H, Thaler M, Kunert H et al. EGFR overexpression induces activation of telomerase via PI3K/AKT-mediated phosphorylation and transcriptional regulation through Hif1-alpha in a cellular model of oral-esophageal carcinogenesis. Cancer Sci. 2011;102(2):351-60.
52. Li H, Gao Q, Guo L, Lu SH. The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther. 2011;11(11):950-8.
53. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta. 1999;1438(1):120-30.
54. Hseu YC, Chen SC, Tsai PC, Chen CS, Lu FJ, Chang NW, et al. Inhibition of cyclooxygenase-2 and induction of apoptosis in estrogen-nonresponsive breast cancer cells by Antrodia camphorata. Food Chem Toxicol. 2007;45(7):1107-15.
55. Moreira L, Castells A. Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets. 2011;12(13):1888-94.
56. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89(12):2637-45.
57. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001;7(4):861-7.
58. Zhang L, Wu YD, Li P, Tu J, Niu YL, Xu CM et al. Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17(41):4572-80.
59. Zhi H, Wang L, Zhang J, Zhou C, Ding F, Luo A, et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis. 2006;27(6):1214-21.
60. Lee CH, Hung HW, Hung PH, Shieh YS. Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. Mol Cancer. 2010;9:64.
61. Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G, et al. The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene. 2005;24(6):1021-31.
62. Mizushima T, Nakagawa H, Kamberov YG, Wilder EL, Klein PS, Rustgi AK. Wnt-1 but not epidermal growth factor induces beta-catenin/T-cell factor-dependent transcription in esophageal cancer cells. Cancer Res. 2002;62(1):277-82.
63. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem. 2002;277(34):30935-41.
64. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 2007;31(3):493-9.
65. Zhang G, Zhang Q, Zhang Q, Yin L, Li S, Cheng K et al. Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. J Cancer Res Clin Oncol. 2010;136(4):587-94.
66. Delektorskaia VV, Chemeris G, Kononets PV, Grigorchuk A. Immunohistochemical study of epidermal growth factor receptor expression in esophageal squamous cell carcinoma. Arkh Patol. 2010;72(5):3-6.
67. Yu WW, Guo YM, Zhu M, Cai XW, Zhu ZF, Zhao WX et al. Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: a meta-analysis. Hepatogastroenterology. 2011;58(106):426-31.